# PRD: Pharma Search & AI Visibility Engine

Sep 26, 2026 · @Abdul Rehman Khan

## TL;DR

We build one platform that gets pharma and health brands found in Google and in AI answers, and gets the content approved in days instead of weeks. Three pillars, one loop:

1. **SEO**: technical audit, content creation and backlinks for Google.
2. **AEO**: prompt tracking against competitors across AI engines, with on-page and off-page actions to win citations.
3. **AI pre-MLR**: every piece of content is reviewed by AI against the label and promotion rules before humans see it. Reviewers only review and sign off.

**The loop:** SEO and AEO find the gaps → the platform drafts the fix → AI pre-MLR makes it approval-ready → humans sign off → it goes live → tracking measures the lift. Generic tools (Profound, Peec, Semrush) stop at step one or two. We own the whole loop, and pillar 3 is why pharma teams can actually use pillars 1 and 2.

**Target:** 50% faster content approval, and measurable visibility lift in Google and AI answers within 120 days of onboarding.

## Problem and why now

Patients and HCPs increasingly ask AI engines about drugs, and pharma sites are poorly built to be cited. IQVIA's March 2026 analysis reported that 54% of HCPs use generative AI in clinical contexts ([pharma-geo.com](https://pharma-geo.com/articles/why-pharma-needs-geo-2026)). Google still dwarfs ChatGPT in volume, so classic SEO still matters too.

Three pharma-specific problems generic tools miss:

1. **Answers can be wrong about the label.** Wrong dosing, missing boxed warnings, or off-label uses in an AI answer are a patient-safety and reputation issue, not just a ranking issue.
2. **Content is gated by MLR review.** Every public claim needs medical, legal and regulatory sign-off, usually in Veeva PromoMats. Generating content is cheap; approving it is the bottleneck.
3. **Enforcement risk is rising.** FDA began a DTC advertising crackdown on September 9, 2025 and has kept issuing letters at a pace far above recent years ([Sidley](https://www.sidley.com/en/insights/newsupdates/2026/03/new-us-fda-letter-contradicts-decades-old-precedent-on-prescription-drug-promotion)). FDA explicitly called out undisclosed paid influencer promotion ([XDS](https://blog.madebyxds.com/healthcare-influencer-marketing-fda-compliance)).

The result: brand teams know they are losing AI share of voice but cannot use generic GEO tools, which push high-volume content and outreach they are not allowed to publish.

## Target customer

First ICP: **mid-size specialty pharma and biotech with 1–5 marketed US brands**. Big pharma buys slowly and via agencies; mid-size teams feel the pain, have budget, and decide in one quarter.

| Persona | Role in deal | What they need |
| --- | --- | --- |
| Brand / digital marketing lead | Champion, budget owner | Share of voice in AI and search vs competitors, a plan to improve it |
| Medical affairs / medical information | Co-buyer, strongest pain on accuracy | Alerts when AI answers contradict the label |
| MLR reviewers (regulatory, legal) | Gatekeeper | Content that arrives pre-referenced and claim-tagged |
| Pharmacovigilance | Veto holder | Assurance that monitoring does not create unmanaged adverse-event intake |
| Agency of record | Channel or competitor | A tool that makes their retainer look better |

Open question: sell to the brand team with medical affairs as ally, or lead with medical affairs (accuracy) and expand into brand (growth)?

## Competitive landscape

The horizontal category is crowded and well funded; the pharma-compliant slice is mostly agencies and consultants. We win only if we are the obvious pharma choice, not a cheaper Profound.

| Player | Type | Relevance to us |
| --- | --- | --- |
| [Profound](https://siliconangle.com/2026/09/15/profound-raises-180m-to-boost-brands-visibility-in-ai-services/) | Horizontal GEO leader | Raised $180M at $1.8B valuation (Sep 15, 2026); agents that research, write and publish; HIPAA-compliant claim. Will move into pharma if it is big enough. |
| Semrush, Ahrefs, Moz | Classic SEO suites | All have added AI visibility; already inside pharma agencies. Integrate, don't fight. |
| [Writesonic](https://en.wikipedia.org/wiki/Writesonic) | Content-led GEO | Tracks many AI engines, generates content and off-site mentions. No MLR awareness. |
| Pharma GEO agencies and indexes (e.g. [PharmaGEO](https://pharma-geo.com/articles/why-pharma-needs-geo-2026)) | Service | Prove demand; run $3k–$20k/month programs ([Digital Elevator](https://thedigitalelevator.com/blog/best-geo-agencies-biotech-life-sciences/)). Possible channel partners. |
| Veeva (PromoMats, CRM) | Pharma system of record | Owns MLR workflow. Must integrate; biggest long-term platform risk. |

**Positioning:** "The AI visibility platform built for MLR." Differentiators: label-grounded accuracy checks, claim-referenced content drafts, PromoMats export, adverse-event-aware monitoring, therapeutic-area prompt libraries.

## Product principles

1. **The label is the source of truth.** Every generated claim links to the approved prescribing information or an approved reference. Unreferenced claims are blocked, not flagged.
2. **Draft, never publish.** The product produces MLR-ready drafts and exports them for review. Nothing goes live without human approval.
3. **On-label by default.** Keyword and prompt suggestions outside the approved indication are hidden from content generation and shown only as monitoring signals.
4. **Safety events are routed, not stored.** Any monitored content that may describe an adverse event goes to the customer's pharmacovigilance process per their SOP.
5. **Disclosure is built in.** Any earned-media or creator workflow produces disclosure and fair-balance requirements up front.
6. **Measure honestly.** AI answers vary by model, region and time; every visibility score shows sample size and confidence.

## Build plan

We ship in four releases, each one sellable on its own. Monitoring comes first because it sells the audit; pre-MLR comes early because it is the reason pharma buys.

| Release | Timing | SEO | AEO | AI pre-MLR |
| --- | --- | --- | --- | --- |
| R1 — See the gaps | Months 0–3 | Technical audit, rank tracking, keyword import | Prompt tracking vs competitors, citation map, share of voice | Label and claims ingestion |
| R2 — Fix owned | Months 3–6 | Content briefs and drafts, schema fixes | On-page recommendations, AI-ready page drafts | Pre-review v1: claim matching, fair balance, ISI, banned phrases; Veeva export |
| R3 — Win earned | Months 6–9 | Backlink gap finder, digital PR briefs | Off-page map: who cites competitors not us; outreach workflows | Pre-review of outreach and PR materials |
| R4 — Automate | Months 9–12 | Programmatic templates (unbranded) | Misinformation correction workflow | Reviewer copilot, auto-routing, learning from reviewer edits |

Consumer-health and wellness brands (OTC, devices, telehealth) get every feature from day one. Rx brands get the same features with Rx guardrails switched on (see Guardrails).

**Go-to-market: two doors, one product.**

- **Self-serve (mid-size pharma, OTC, biotech):** type the company website, get a free first scan in about 5 minutes, sign up only to save the report, convert after the first approved fix. Full flow in the User Journey doc.
- **Sales-led (big pharma, agencies):** demo on their brand, paid pilot under procurement thresholds, design-partner terms, security review (SOC 2) before rollout.
- Both doors land in the same product; "Book a walkthrough" is always a secondary option on the self-serve path, never a gate.

## Platform foundation

All three pillars run on one shared brand model. It is what makes the SEO and AEO output compliant by default.

**Brand and label model**

- Ingest the prescribing information (DailyMed/SPL in the US, SmPC in the EU), the approved claims library, indications, ISI and brand guidelines.
- Store competitors, therapeutic area, audiences (patient, caregiver, HCP) and markets.
- Import existing keywords from Semrush, Ahrefs or CSV, and past approved content from Veeva PromoMats.

**Regulatory tier per brand**

| Tier | Examples | Default settings |
| --- | --- | --- |
| Rx | Specialty and primary-care drugs | Claims-grounded content only; fair balance and ISI enforced; no paid endorsements |
| OTC / consumer health | Pain, allergy, digestive | Reviews and creator programs on; monograph-aligned claims |
| Telehealth | DTC prescribing platforms | Rx rules on product claims; open content on conditions and care |
| Device / wellness | Wearables, apps, supplements | All growth features on; claim checks for disease claims |

**Query lanes.** Every keyword and prompt is auto-classified into a lane that decides what the platform does with it:

| Lane | Example | Action |
| --- | --- | --- |
| Branded, on-label | "how does \[drug\] work" | Generate claims-grounded content → pre-MLR |
| Unbranded disease | "early signs of psoriatic arthritis" | Generate educational content, fast review track |
| Competitor comparison | "\[drug A\] vs \[drug B\]" | Content only where head-to-head data exists; otherwise monitor |
| Off-label | "can \[drug\] treat X" | Monitor and route to medical affairs |
| Misinformation | AI states the wrong dose | Correction workflow |
| Possible adverse event | User describes a side effect | Route to pharmacovigilance |

## Pillar 1 — SEO

Goal: rank the brand's owned sites for every on-label and disease-awareness query that matters, and build the authority to hold those rankings.

### 1A. Technical SEO audit

- Crawl brand, HCP, corporate and disease-awareness sites on a schedule.
- Standard checks: indexability, canonicals, redirects, Core Web Vitals, mobile, internal linking, sitemaps, hreflang for multi-market brands.
- Pharma-specific checks:
  - Key information locked in PDFs (label, patient guides) → recommend HTML versions.
  - ISI rendering: sticky ISI blocks that hide main content from crawlers.
  - HCP gates ("Are you a healthcare professional?") blocking indexing of content that could be public.
  - Schema: Drug, MedicalCondition, MedicalWebPage, FAQPage, Organization.
  - AI crawler access (GPTBot, PerplexityBot, Google-Extended) and llms.txt.
- Output: prioritized fix list with estimated traffic impact, exportable as developer tickets (Jira, Asana).

### 1B. Content creation

- Keyword gap analysis vs named competitors, grouped into topic clusters per lane.
- Content briefs: target query, search intent, outline, required claims and references pulled from the claims library.
- Full drafts: patient pages, HCP pages, disease-awareness articles, FAQs, glossary pages.
- Refresh engine: flags pages that lost rankings or whose claims no longer match the current label.
- Every draft goes straight into pillar 3 before anyone sees it.

### 1C. Backlinks and authority

- Backlink gap: domains linking to competitors but not to us, scored by authority and relevance to the therapeutic area.
- Source classes: medical societies, patient advocacy groups, hospitals and universities, health publishers, journals, news, pharmacy and formulary sites.
- Link-earning assets the platform suggests and drafts: disease-burden data studies, symptom checkers, calculators, patient-support resources, press-ready research summaries.
- Outreach drafts per target, pre-reviewed by pillar 3, sent from the user's own email with tracking.
- Unlinked brand mentions → reclaim requests.

## Pillar 2 — AEO

Goal: the brand is mentioned, accurately described and cited in AI answers for the questions patients and HCPs actually ask.

### 2A. Prompt tracking vs competitors

- Prompt library per therapeutic area and audience, auto-generated from the brand model and editable. Starter libraries for top therapeutic areas (obesity, immunology, oncology, CNS, cardio, women's health).
- Scheduled runs across ChatGPT, Gemini, Google AI Overviews and AI Mode, Perplexity, Claude, Copilot and Meta AI; multiple samples per prompt, by market and language.
- Per prompt: mentioned or not, position in answer, sentiment, citations, competitors mentioned.
- **Accuracy score:** each answer checked against the label (dose, indication, boxed warning, contraindications). Pharma-only metric, shown next to share of voice.
- Dashboards: share of voice by engine, audience, lane and time; alerts on drops, new competitor wins and accuracy errors.

### 2B. On-page actions

- For every lost prompt: which page should win it, and what is missing (no direct answer, answer buried in PDF, no schema, no FAQ, weak entity signals).
- Drafts AI-ready content: direct-answer blocks, Q&A sections, comparison tables where data allows, clear dosing and safety summaries.
- Entity work: consistent brand, molecule and company naming; structured data; Wikidata and knowledge-panel checks.
- All drafts flow into pillar 3.

### 2C. Off-page actions

- **Citation map:** which domains each engine cites per prompt (FDA/DailyMed, journals, medical societies, WebMD-type publishers, Reddit, YouTube, advocacy groups).
- **Competitor-only sources:** YouTube channels, LinkedIn posts, blogs, podcasts and articles that mention competitors but not us, ranked by how often AI engines cite them.
- Action per source, set by regulatory tier: PR pitch, medical affairs education, advocacy partnership, publication plan, correction request, or creator program (OTC/wellness).
- **Misinformation correction:** when an AI answer or a cited page is wrong, draft a correction following FDA's misinformation guidance, send to the source, and track whether the AI answer changes.

### 2D. Recommendations engine

- Weekly prioritized action list across SEO and AEO: "do these 10 things," each with expected impact, effort, lane and review track.
- One click turns a recommendation into a brief, a draft or an outreach task.

## Pillar 3 — AI pre-MLR

Goal: AI does the checking, fixing and referencing; medical, legal and regulatory reviewers only review and sign off. Target: approval cycle down from the typical 24–45 days per asset to under 10.

### 3A. Automated review

Every draft, whether generated here or uploaded from an agency, gets checked before a human sees it:

- **Claim matching:** each claim linked to the label or an approved reference; unsupported claims highlighted with a suggested fix or a matching approved claim.
- **Fair balance:** risk information present, proportional and as prominent as benefits.
- **ISI and required statements** present and current.
- **Language rules:** superlatives, "cure," "safe," unapproved comparisons, overstated efficacy, missing "in clinical studies" qualifiers.
- **Off-label drift:** content implying uses, populations or doses outside the label.
- **Overall impression check:** headline vs body, imagery and layout flags for human attention.
- **Market rules:** US (FDA/OPDP) first; EU, UK (ABPI/PMCPA) and other codes as configurable rule packs.

### 3B. Auto-fix and annotate

- AI rewrites flagged passages and shows before/after.
- Produces the reviewer package: annotated draft with reference links, claim-to-source table, change log and risk score.
- Low-risk content (e.g. unbranded awareness, updates to already-approved pages) marked for a fast track.

### 3C. Human review and sign-off

- Reviewer workspace: approve, reject or comment per claim, not per document.
- Export to Veeva PromoMats with annotations and references attached; native review UI for teams without Veeva.
- Named sign-off by medical, legal and regulatory with a full audit trail.

### 3D. Learning loop

- Every reviewer edit and rejection trains brand-specific rules ("this reviewer never accepts X").
- First-pass approval rate tracked per content type; rules improve until most drafts pass on round one.

## Guardrails

These are what let us ship aggressive growth features to pharma buyers. Each one is a selling point to compliance, not a limit on the product.

- **Human sign-off before publish.** The platform drafts, reviews and packages; people approve. Nothing auto-publishes for Rx brands.
- **Tier-aware features.** Reviews, creator programs and programmatic pages are on for OTC, device and wellness tiers. For Rx they switch to compliant equivalents: unbranded programmatic templates, medical-affairs and PR outreach instead of paid endorsements.
- **Disclosure built in.** Any paid partnership workflow requires disclosure, contract and fair-balance fields before it can be sent.
- **Safety routing.** Possible adverse events found anywhere in monitoring go to the customer's pharmacovigilance inbox under their SOP.
- **Audit trail.** Every claim, edit, reviewer action and AI suggestion is logged and exportable for inspections.
- **No patient PHI** in the product.

## Success metrics

North star: **approved fixes live per brand per month**, content that passed review, went live and moved visibility.

| Pillar | Metric | 12-month target |
| --- | --- | --- |
| SEO | Organic clicks on tracked keyword clusters | +40% vs baseline |
| SEO | Critical technical issues resolved | 80% within 90 days |
| SEO | New referring domains from target classes | 25+ per brand per quarter |
| AEO | AI share of voice on tracked prompts | +15 points vs baseline |
| AEO | AI answer accuracy vs label | 95%+ of sampled answers |
| AEO | Competitor-only sources converted to mentions | 10+ per brand per quarter |
| Pre-MLR | Median days from draft to approval | Under 10 (from 24–45) |
| Pre-MLR | First-pass approval rate | 60%+ |
| Pre-MLR | Reviewer hours per asset | −50% |
| Business | Paying brands | 20 by month 12 |
| Business | Net revenue retention | 120%+ |

## Architecture

Buy the commodity data, build the pharma intelligence. Speed comes from licensing what exists; the moat comes from the label model, lanes and review engine.

| Component | Pillar | Build or buy | Notes |
| --- | --- | --- | --- |
| Keyword, rank, backlink data | SEO | Buy | DataForSEO or Semrush API; import from customers' own tools |
| Site crawler | SEO | Buy / open source + build | Pharma checks (ISI, PDFs, HCP gates, schema) on top |
| AI answer collection | AEO | Build | Official APIs plus browser sampling; repeated runs per prompt for confidence intervals |
| Citation and source graph | AEO | Build | Domains cited per prompt, per engine, over time |
| Off-page discovery | SEO + AEO | Build on APIs | YouTube Data API, podcast indexes, news, web search; LinkedIn via compliant data partners |
| Label and claims store | All | Build | DailyMed/SPL parsing, claims library, SmPC later |
| Lane classifier | All | Build | LLM + rules, evaluated on labelled pharma queries |
| Review engine | Pre-MLR | Build | LLM checks grounded in the label plus deterministic rule packs per market |
| Veeva PromoMats integration | Pre-MLR | Integrate | Vault API; PDF/Word fallback |
| Outreach | SEO + AEO | Integrate | Gmail/Outlook sending with tracking |
| Security | All | Build | SOC 2 Type II, SSO, per-brand data isolation, full audit log |

## Hard problems and how we solve them

| Problem | How we solve it |
| --- | --- |
| Reviewers won't trust AI review | Show every flag with its source; measure precision per brand; start with low-risk content to earn trust fast |
| Generic tools add a "pharma" edition | Label model, lane classifier, rule packs and Veeva integration take years to copy; we lock in design partners first |
| Long pharma sales cycles | Land with the audit (R1) as a paid pilot under procurement thresholds; start with mid-size pharma, OTC and telehealth |
| AI answers are noisy | Repeated sampling, confidence intervals, published methodology |
| Backlinks are hard in health | Link-earning assets (data studies, tools) instead of link requests; relationships with societies and advocacy groups |
| Regulation keeps shifting | Rule packs updated centrally; tier settings mean new rules ship as config, not code |

## First 90 days

- [ ] Sign 5 design partners: 2 Rx, 2 OTC/consumer health, 1 telehealth or device
- [ ] Ship R1: technical audit, prompt tracking vs competitors, citation map, label ingestion
- [ ] Build the pre-MLR v1 rule set with 2 partner MLR teams, using their past approved and rejected content
- [ ] Publish a monthly AI visibility index for one therapeutic area as the marketing engine
- [ ] Convert 3 design partners to paid contracts

## Sources

- [SiliconANGLE: Profound raises $180M](https://siliconangle.com/2026/09/15/profound-raises-180m-to-boost-brands-visibility-in-ai-services/)
- [Sidley: FDA promotion enforcement 2026](https://www.sidley.com/en/insights/newsupdates/2026/03/new-us-fda-letter-contradicts-decades-old-precedent-on-prescription-drug-promotion)
- [XDS: Healthcare influencer marketing and FDA](https://blog.madebyxds.com/healthcare-influencer-marketing-fda-compliance)
- [PharmaGEO: Why pharma needs GEO in 2026](https://pharma-geo.com/articles/why-pharma-needs-geo-2026)
- [Digital Elevator: GEO agencies for life sciences](https://thedigitalelevator.com/blog/best-geo-agencies-biotech-life-sciences/)
- [Writesonic (Wikipedia)](https://en.wikipedia.org/wiki/Writesonic)
- [AWS: Life Sciences Symposium, MLR turnaround of 24–45 days per asset](https://aws.amazon.com/blogs/industries/highlights-from-the-2025-aws-life-sciences-symposiums-commercialization-track/)
- [FDA: Revised draft guidance on addressing misinformation](https://www.fda.gov/news-events/press-announcements/fda-updates-guidance-further-empower-companies-address-spread-misinformation)
- [Veeva: Next-gen MLR review with AI](https://www.veeva.com/resources/building-the-future-of-mlr-with-ai-fastest-path-to-approved-content/)
